Bharat Biotech developed the vaccine which prevents chronic diarrhea in children. The vaccine is soon to be introduced in the national immunization programme.

Over Rs 400 crore was invested and more than 15 years of research has gone into the development of the vaccine. The investment was partly funded by the Bill and Melinda Gates Foundation and the department of biotechnology and also got support from various international agencies.
"In 2001, I made a commitment to the Gates Foundation to develop and supply a novel Rotavirus vaccine at $1 a dose for government programmes. The price of the vaccine in the retail market, however, is going to match the price charged by multinational competitors US-based Merck Sharp & Dohme and British firm GlaxoSmithKline for the same product,” Ella indicated.
Bharat Biotech has got multiple patents for the drug in over 50 countries, including the US, several European countries and Japan. "Our Hyderabad-based facility has the capacity to make over 300 million doses per year and we are in talks with some developing countries besides international agencies to export the vaccine but those opportunities will take a year and half probably to fructify," said Ella.
Source-Medindia